InspireMD

NSPR

Market cap $80.9M

Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis

MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to eight (8) new non-executive employees in the aggregate amount of 122,054 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of November 20, 2025, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to participate in a fireside discussion at the upcoming Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd at 12:30 pm Eastern Time (ET).

InspireMD, Inc. ( NSPR ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Marvin Slosman - President, CEO & Director Michael Lawless - Chief Financial Officer Shane Gleason - Chief Commercial Officer Conference Call Participants Webb Campbell Adam Maeder - Piper Sandler & Co., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good morning, and welcome to InspireMD Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.

Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue

MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention.

MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m.

MIAMI, Oct. 08, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to three (3) new non-executive employees in the aggregate amount of 40,513 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of October 7, 2025, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

MIAMI, Sept. 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to five (5) new non-executive employees in the aggregate amount of 88,324 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of September 24, 2025, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).